Get the latest tech news
So you wanna build an aging company
So you wanna build an aging company?
Simple physical-function tests such as gait speed or the Short Physical Performance Battery (SPPB) consistently outperform individual blood biomarkers, and often rival sophisticated multi-marker panels, in predicting long-term mortality. Improving immune function tackles a root cause of age-related disease, but reducing the risk of (especially respiratory) infection is also immediately measurable and consequential, since influenza and COVID-19 are leading causes of death in the elderly. Because metabolic dysfunction precedes cardiovascular, neurodegenerative, and fibrotic disease, drugs that target it could be viable “geroprotectors.” GLP-1 agonists already show substantial cardio-renal benefits in humans and, in preclinical work, reverse multi-omic aging signatures and modestly extend lifespan in fast-aging mice.
Or read this on Hacker News